Dalmia Healthcare Starts Clinical Trial with its Ayurvedic Composition to Treat COVID-19

New Delhi, June 04, 2020: Dalmia Healthcare, the healthcare division of Dalmia Group led by renowned industrialist Sanjay Dalmia, starts clinical trial to evaluate the efficacy and safety of polyherbal combination “Astha-15” for treatment of COVID-19. The Dalmia Centre for Research and Development (DCRD), R&D entity of Dalmia Group after years of extensive research, manufactured a polyherbal combination of 15 herbs called Astha-15, also mentioned in the Indian System of Medicine. Set regulatory guidelines of Informed Consent Declaration, Insurance Terms and EC approvals will be followed to conduct the Multi-centric, Phase III clinical trials. This phase III clinical trial has been registered on CTRI with reg. no. CTRI/2020/06/025590.

The study comes in the back of the Ministry of AYUSH last month recommending the use of herbal products like tea, spices, to overcome the pandemic. The polyherbal combination “Astha-15“, made available by the Group on March 16, has previously undergone a randomized double-blind, placebo-controlled study on patients, in speciality Govt. Hospital, Chennai, India. As per the double-blind study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and didn’t show any side-effects. Now this polyherbal combination “Astha-15” will undergo a phase III clinical trial with the most primary COVID-19 sites across India under the supervision of highly skilled physicians.